Article

Body Mass Index Genotype Linked to Breast Cancer Risk

Premenopausal, overweight women have a decreased risk of breast cancer, while postmenopausal women have an increased risk.

Women with a high body mass index (BMI) before menopause was associated with a decreased risk of breast cancer, but an increased risk of the disease after menopause.

In a study published in PLOS Medicine, researchers used data from 145,056 women. They also used a list of genetic variants found to be associated with BMI in genomic studies.

Each woman’s BMI was estimated based solely on genotype. The results of the study showed that genetically predicted high BMI was associated with a reduce risk of breast cancer in both premenopausal and postmenopausal women.

“It is likely that genetically predicted BMI may be more closely related to body weight in early life, which is negatively associated with breast cancer risk,” said researcher Wei Zheng, PhD, MD. “Measured high BMI later in life may be influenced primarily by environmental factors that are associated with increased risk of breast cancer. For breast cancer prevention, the study provides evidence for lifestyle modification to reduce weight gain in adults.”

Related Videos
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Image Credit: © Krakenimages.com - stock.adobe.com
Image Credit: © Cavan - stock.adobe.com